Publication | Closed Access

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial

First-line TherapyUrologyAxitinib Versus SorafenibMetastatic Renal-cell CarcinomaGenitourinary CancerMedicineClinical TrialsPharmacotherapyCancer TreatmentOncologyMolecular Oncology